Cargando…

Single-Cell Analysis Suggests that Ongoing Affinity Maturation Drives the Emergence of Pemphigus Vulgaris Autoimmune Disease

Pemphigus vulgaris (PV) is an autoimmune disease characterized by blistering sores on skin and mucosal membranes, caused by autoantibodies primarily targeting the cellular adhesion protein, desmoglein-3 (Dsg3). To better understand how Dsg3-specific autoantibodies develop and cause disease in humans...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Alice, Caldara, Amber L., Ran, Nina A., Menne, Zach, Kauffman, Robert C., Affer, Maurizio, Llovet, Alexandra, Norwood, Carson, Scanlan, Aaron, Mantus, Grace, Bradley, Bridget, Zimmer, Stephanie, Schmidt, Thomas, Hertl, Michael, Payne, Aimee S., Feldman, Ron, Kowalczyk, Andrew P., Wrammert, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684256/
https://www.ncbi.nlm.nih.gov/pubmed/31340153
http://dx.doi.org/10.1016/j.celrep.2019.06.066
Descripción
Sumario:Pemphigus vulgaris (PV) is an autoimmune disease characterized by blistering sores on skin and mucosal membranes, caused by autoantibodies primarily targeting the cellular adhesion protein, desmoglein-3 (Dsg3). To better understand how Dsg3-specific autoantibodies develop and cause disease in humans, we performed a cross-sectional study of PV patients before and after treatment to track relevant cellular responses underlying disease pathogenesis, and we provide an in-depth analysis of two patients by generating a panel of mAbs from single Dsg3-specific memory B cells (MBCs). Additionally, we analyzed a paired sample from one patient collected 15-months prior to disease diagnosis. We find that Dsg3-specific MBCs have an activated phenotype and show signs of ongoing affinity maturation and clonal selection. Monoclonal antibodies (mAbs) with pathogenic activity primarily target epitopes in the extracellular domains EC1 and EC2 of Dsg3, though they can also bind to the EC4 domain. Combining antibodies targeting different epitopes synergistically enhances in vitro pathogenicity.